# Dose-finding Study of LFB-R593, A Monoclonal Anti-RhD Antibody, in Healthy RhD Negative Volunteers

> **NCT00952575** · PHASE2 · COMPLETED · sponsor: **Laboratoire français de Fractionnement et de Biotechnologies** · enrollment: 78 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** polyclonal anti-D immunoglobulin
- **DRUG:** monoclonal anti-D immunoglobulin

## Key facts

- **NCT ID:** NCT00952575
- **Lead sponsor:** Laboratoire français de Fractionnement et de Biotechnologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2011-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00952575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00952575, "Dose-finding Study of LFB-R593, A Monoclonal Anti-RhD Antibody, in Healthy RhD Negative Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00952575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*